Information  X 
Enter a valid email address

Synairgen plc (SNG)

  Print      Mail a friend       Annual reports

Thursday 15 October, 2020

Synairgen plc

Director/PDMR Shareholding

RNS Number : 2402C
Synairgen plc
15 October 2020
 

 

Synairgen plc

("Synairgen" or the "Company")

 

Director Dealing/PDMR Announcement

 

Further to the announcement earlier today regarding the Placing, the Company makes the below announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014) in respect of the exercise of options by Richard Marsden, CEO of the Company, and John Ward, Finance Director of the Company.

 

Enquiries:

Synairgen plc                                                                                                      +44 (0) 23 8051 2800

Richard Marsden (Chief Executive Officer)

John Ward (Finance Director)

finnCap - Nominated Adviser and Joint Bookrunner                                +44 (0) 20 7220 0500

Geoff Nash / James Thompson / Charlie Beeson (Corporate Finance)

Alice Lane / Sunila de Silva (ECM)

Numis - Joint Bookrunner                                                                                +44 (0) 20 7260 1000

James Black / Freddie Barnfield / Duncan Monteith

Consilium Strategic Communications - Financial Media and Investor  +44 (0) 20 3709 5700

Relations Adviser

Mary-Jane Elliott / Sue Stuart / Olivia Manser

 

 

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma, COPD and COVID-19, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

 

 

1.

Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')

a)

Name

R ichard Marsden

2.

Reason for notification

a)

Position / status

Chief Executive Officer

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s):

a)

Description of the financial instrument

Identification code

O ptions over o rdinary shares of 1p each


GB00B0381Z20

b)

Nature of the transaction

Exercise of options over Ordinary Shares

 

c)

Price(s) and volume(s)

386,842 Ordinary shares of 1p each

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

15 October 2020

f)

Place of the transaction

London Stock Exchange

 

1.

Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')

a)

Name

John Ward

2.

Reason for notification

a)

Position / status

Finance Director

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s):

a)

Description of the financial instrument

Identification code

O ptions over o rdinary shares of 1p each


GB00B0381Z20

b)

Nature of the transaction

Exercise of options over Ordinary Shares

 

c)

Price(s) and volume(s)

147,330 Ordinary shares of 1p each

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

15 October 2020

f)

Place of the transaction

London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAAESFLNEFFA

a d v e r t i s e m e n t